The aims of this study were to determine the total cost of drug treatment in patients of rheumatoid arthritis, to estimate the costs of management of gastrointestinal side effects of non-steroidal antiinflammatory drugs and to estimate the cost of monitoring the side-effects of disease modifying antirheumatic drugs. The original prescription of the patients was used to calculate the direct cost of treatment. For calculating the indirect cost, the patients were interviewed. The cost of monitoring the side-effects was also calculated from the patient records. The study was carried in out patient department of a government teaching hospital. A total of 96 patients were recruited in this study between August-November 2003. The average total cost of drug treatment was found to be Rs.999±76 per month. The average monthly direct cost of rheumatoid arthritis was estimated to be Rs. 623±31. The average indirect cost was found to be Rs.368±62 per month. The average iatrogenic cost factor value was found to be 1.78. The average monthly cost of monitoring side-effects in patients prescribed with disease modifying antirheumatic drugs was Rs. 57 per patient. The study provides preliminary results for costs of drug treatment and monitoring in patients suffering from rheumatoid arthritis.
In chronic illnesses, the outcomes are largely dependent aid the rheumatologists while making the choice of upon the adherence to the drug therapy according to the drug(s) for the patient. It is not only the physicians' prescribed regimen. In achieving this goal, the preference but also the patients' preference that should pharmacoeconomic evaluation plays a dominant role since be kept into consideration while selecting a drug. It has the costs and stakes of therapy in a chronic disease are been demonstrated 4 that the patients are more compliant high. Such analysis of cost assumes more relevance when to etodolac-SR once daily than the conventional dosage both direct and indirect as well as the social costs are form. However, if the disease were effectively controlled high as in case of rheumatoid arthritis (RA) 1 . The patients early, there would be long-term benefits to be offset suffering from RA fall into a clinical spectrum ranging against the higher treatment cost 5, 6 . It has been shown from a slowly progressive to a rapidly progressive and that if DMARDs are used since the onset of disease, it aggressive course. And, the drug treatment of patients leads to improvement in disability index values 7 . Of late, has witnessed a paradigm shift in the recent past.
leflunomide and tissue necrosis factor alpha antagonists
The available evidence suggests that maximal success in pharmacotherapy of RA depends largely on early and aggressive medical therapy 2 . Further, it is also becoming increasingly clear that disease modifying antirheumatic drugs (DMARDs) should be introduced as soon as possible www.ijpsonline.com
This study, preliminary in nature, aimed to determine the total cost of drug treatment in case of patients of RA, to estimate the costs of management of gastrointestinal sideeffects of NSAIDs and to estimate the cost of monitoring side-effects of DMARDs.
MATERIALS AND METHODS
The study was conducted at a government teaching hospital. The patients fulfilling the ACR 1987 criteria for RA 14 , attending out patient rheumatology clinic at represented as mean±standard error of the mean (along with other statistical parameters).
The cost of monitoring the side-effects of the NSAIDs was calculated using the ICF value. This value reflects an estimate of the additional costs associated with treating adverse events arising out of the treatment with NSAIDs. The ICF value is the ratio of the total daily cost of NSAID therapy (cost of NSAID plus cost of additional gastro-protective agent required such as proton pump inhibitor) to the daily cost of the NSAID only. Even if the Government Medical College, Chandigarh, were enrolled.
gastro-protective agent was used for the prophylaxis, it The patients who were freshly diagnosed of rheumatoid was included in the ICF calculation. Further, the cost of arthritis and who were presenting any co-morbid monitoring side-effects of the DMARDs -like eye condition in the out patient department were excluded checkup with hydroxychloroquine treatment and complete from the study. A total of 96 patients were recruited blood count, liver function test, renal function test (with between August-November 2003. The patients with the use of methotrexate, sulphasalazine, leflunomide) was incomplete information about their medication and/or also calculated. laboratory tests were excluded from analysis of the determination of the costs.
RESULTS AND DISCUSSION
For calculating the direct cost, the original prescription of Of the 93 patients in this study, over 75% of the patients patient was used. The direct cost of treatment included were females. The prevalence of RA is known to be three the amount charged by the hospital, cost of the drugs times higher in females than the males. The age profile of prescribed and the cost of the laboratory tests performed.
the 93 patients reflected that approximately 60% patients The amount charged by the hospital was not included in were in the age group of 40-60 y ( fig. 1 ). It was noted that this study because it is the one time charged cost while almost half of the patients (48%) enrolled in the study had making the hospital card and the patient does not pay it never been to the school. The number of graduate and on the follow up visits.
post-graduate patients was very small and they comprised approximately only one-fifth of the total patient population The calculation of the costs of drugs prescribed was of the study. Secondly, only a small fraction of patients performed using the current issue of Current Index of (18%) had the facility of medical reimbursement ( fig. 2 ). Medical Specialties (CIMS) 15 . In cases where generic However, the reimbursement was not sufficient to cover drugs were prescribed, either the patient was interviewed the cost of therapy in 32% of the cases ( fig. 2 ). This regarding the specific drug being taken or in the shows that a very large proportion of the patients absence of this information, the average cost of the drug depended on their own income source (or the family) for was used. The cost of laboratory tests in the hospital the treatment of RA. It was found that none of the patients varies depending upon the income of the patient (or the had any kind of health insurance cover. family). In this study, the costs charged to the middle income category (group B whose monthly income
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Rs. 1000-3000) patients were taken into the consideration ) .
The average indirect cost was found to be Rs. 368±62 per month ( fig. 3 ). The direct cost includes the costs of drugs for the month and laboratory tests performed in that particular month. It was estimated that average expenditure on drugs was Rs. 530±30 (mode Rs. 353) and average expenditure on laboratory tests was Rs. 90±0.18 (mode Rs. 115).
DMARDs contributed 47% of the proportion of the cost cost is high for these drugs. Forty out of 93 patients were on steroids (43%) and majority of the patients were prescribed with prednisolone. A combination of DMARDs was prescribed to 13 patients, out of which 11 were on a two-drug combination and only 2 patients were on 3 drugs combination (Table 1) . A very large number of patients were prescribed with the combination of hydroxychloroquine and methotrexate.
The rank order of indirect costs is represented in fig. 5 . In the descending order of magnitude it was found to be travel> income of the accompanying person> amount spent on the hel P> income due to loss of work (60%, 16%, 14% and 10%, respectively).
The average amount of money spent on travel was www.ijpsonline.com
The determination of the total cost of treatment of RA (n= 93) revealed that the average total cost of treatment in RA was Rs.999±76 per month (mode Rs. 910). The distribution of the total cost was, however, not normal ( fig.  3 ). The cost of treatment in RA depends upon various factors (like disease progression, the severity of the disease, the mode/distance of travel, the daily income of the patient and so on) and this may be the reason for the variations seen in the data on total cost. The total cost comprised direct and indirect costs. The average monthly direct cost was estimated to be Rs. 623±31 (mode Rs. 781).
followed by the NSAIDs (36% contribution) and the folic acid supplements (prescribed only to the patients on methotrexate) was the last ranking category (fig. 4) . Only 43 out of 93 patients, especially women over 50 yrs who were post-menopausal, were put on calcium supplements in order to avoid the chances of osteoporosis. This contributed to 10% of the total spending on the drugs. For a limited number of nine patients, supplements like glucosamine and iron were also prescribed depending on the individual requirement, and they contributed 4% to total cost. This is due to the fact that the drug acquisition Rs.239±54. The relatively large variation in amount spent on travel can be attributed to the fact that the distance also noted that none of the patients required hospitalization due to GI side effects. This study has made a preliminary attempt to estimate the and 60% of the total population falls in the age group of total cost of drug treatment, the costs of management of 40-60 y. With less than one fifth of patients having gastrointestinal side effects of NSAIDs and the side reimbursement facility, the economic burden of treating effects of DMARDs in chronic patients of RA. The RA lied on their family. The loss of the income of the results are based upon the data obtained from 93 patient depended on the type of job of the patient and it patients. The average total cost of treatment of RA was ranged between Rs. 60-Rs.1200. Similarly, the loss of found to be Rs.999±76 per month, which is very close income of accompanying person also depends on type of to the mode of the data. The monthly direct cost was job and varied between Rs. 30-1000. Only 6 patients found to be Rs. 623±31. In this case, however, the required household help and amount spent varied from mode (Rs. 781) is larger than the average of Rs. 623; this Rs. 500-1000. It is expected because either people reflects positive skew in the direct cost data. The usually live in joint families or belong to lower income monthly direct cost ranged from as low as Rs. 35/-to as group and hence, cannot afford a helping aid.
high as Rs. 1356/-. Further, the average monthly indirect cost was calculated to be Rs. 368±62. However, in this The results showed that 32 patients were prescribed with case the mode is 20, which is much lower than average nonselective COX-2 inhibitors and 51 were prescribed indirect monthly cost. selective COX-2 inhibitors and only very few (3 of 93) patients were prescribed combination of non selective
It is important to note that the costs, in a chronic disease and selective COX inhibitors. Further, it was also found like RA, are usually reported as the annual costs only 10 patients required the prescription of GI because the intensity of symptoms varies between protective agents such as proton pump inhibitor or the Hdifferent seasons. However, since this study is preliminary 2 receptor blockers. Out of these 10 patients, 2 were in nature it will be unreasonable to make comments on prescribed a combination of nonselective and selective the annual costs based on this data. Yet, for the purpose COX-2 inhibitor, 5 were on selective COX-2 inhibitors, 2 of obtaining raw annual estimates, the extrapolation of the were on nonselective COX-2 inhibitors and one was monthly data reveals that the total annual cost of treatment receiving any other NSAIDs. Accordingly, ICF value determination was performed for the limited data of ten patients only. The average ICF value was found to be 1.78 (range 1.22-4.08). This value of ICF indicates that though moderate, yet there is an extra burden of managing the GI side effects. Further, the GI protective agents were prescribed only on the basis of complaints of GI disturbances by the patients. Since no laboratory tests, such as endoscopy, were performed, the subjectivity gets a role to play. Therefore, the drugs used to manage the GI side effects were prescribed without any clinical investigation. Finally, it was of RA is close to Rs .12,000/-, the direct cost Rs. 7,500/ and the approximate indirect cost is Rs. 4,400/-. Such representation of annual data facilitates better comparison with the results of the other researchers.
The results of a US-based study, on patients with early as well as prolonged RA, reported the average annual direct cost of treatment to be US$ 6,000 16 . The patient inclusion criteria are in concurrence with the one used in the current study. Further, the average annual direct cost -generated from 2,32,825 RA patients in UK-was found to be to be GBP 2,597 only 17 . There is a huge difference between the costs of treatment in India and these two www.ijpsonline.com countries. The results of another Dutch study demonstrated the direct costs of treatment of patients with early RA (0-6 yrs) to be Dfl 11,500 18 . Finally, the annual total cost of treatment of RA in Canada was found to be CAN $2162 per patient 1 .
A simplistic comparison of the results of the above studies is not possible because the categories of cost included and methods used differ markedly. For instance, in the study performed in Netherlands 18 , the direct cost included the cost of health care workers, days in care facilities, GI protective agents (either proton pump inhibitors or the H-2 receptor blockers). The epidemiological evidence suggests that NSAIDs increase the risk for lower and upper GI clinical events. However, the COX-2 selective inhibitors decrease the upper GI clinical events but the effect(s) on lower GI event have not been determined. The results from an earlier study, involving 8076 RA patients, demonstrate that serious lower GI events were 54% lower with the use of the selective COX-2 inhibitor (rofecoxib) compared to naproxen 23 . Another study noted that the daily average cost of therapy with rofecoxib in medications, monitoring for side effects, alternative incident cases was € 1.88 which was 7.4% lower than that medicines used and also the adaptations devices required of NSAIDs (€ 2.03), and in prevalent cases it was € by the patients. But in the current study -performed in a 1.87, 28.1% higher than that of NSAIDs (€ 1.46)
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. The public hospital-the cost of health care professionals, the cost due to GI adverse effects amounts to 2-8 times the cost of alternative medicines and the cost of adaptation cost of the original NSAID therapy 10 devices used was not included. Such differences could be easily identified while comparing the studies head to The iatrogenic cost factor (ICF) for NSAIDs gives an head. Including these will bulge the extrapolated annual estimate of the additional costs associated with treating costs of the present study.
adverse The results of Pouvourville and co-workers 27 patients followed for as long as 15 yrs showed US $8,500 that the ICF ranged from 1.36-2.12, depending on the as the total medical costs. Nearly 70% of this amount was NSAID taken. However, the co-prescription with GI directly related to treatment of the disease. Hospital protective agents was not included. The average ICF admissions accounted for over half of this in spite of the value, in the present study, was found to be 1.78 (range fact that less than one-tenth of the study group was 1.22-4.08). The GI protective agents were prescribed on hospitalized in any given year. The drugs accounted for the basis of patients' complaints of GI disturbances; a quarter of the direct cost, with cost of DMARDs however, no laboratory tests were performed. In this compromising 75% out of that quarter spent as direct cost study, the drugs were prescribed on the clinical judgment expense 19 . Further, in the present study 47% of the total of the physician. It was largely due to the reason that amount spent on drugs was on the DMARDs. The second none of the patients presented with a complication largest group of drugs used was analgesics -contributing requiring a clinical investigation or has to be hospitalized 35% to the total spending on drugs. It was also observed due to GI side effects. that the cost of drugs was not uniformly distributed throughout the patient population but rather was highly In this study, leflunomide (prescribed only to 11 patients)
.
showed the ICF confirmed ICF to lie showed skewed towards those patients with the worst functional status 20 . The functional status of individual is known to be the most consistent and strongest determinant of cost. The results of this study demonstrate a significant association between deformity in the patient and direct cost (P=0.001). A similar skewing of costs towards those with greater disability has also been noted in other cost studies of RA 18, 21, 22 .
In this study, a very limited number of patients were prescribed with the COX-1 inhibitors; and of them, very few patients reported GI adverse effects. Of the 93 patients in this study, only 10 were prescribed with the was found to be most expensive drug as per the acquisition costs. The conventional drugs, like gold and pencillamine, were not prescribed frequently; none of the patients was prescribed gold and only one patient was prescribed with pencillamine. Prashker and Meenan 28 considered the total cost of drug to be composed of 3 components viz., the actual cost of drug, the cost of monitoring patients for potential side effects of the drug and the cost of treating the side-effects when they occur. They noted that the cost of monitoring and treating side effects contributed to over 60% of the total cost of all medications except injectable gold. When the total costs were compared, it was found that while oral gold was the www.ijpsonline.com cheapest the injectable gold was the most expensive. Further, they reported methotrexate to be the most expensive drug in terms of monitoring costs. The results of the present study demonstrate that Methotrexate was the cheapest drug in terms of acquisition; however, it is the most expensive drug in terms of monitoring the side effects since regular (every 4 weeks) liver function test, renal function tests and complete blood count are required.
In the present study, the cost of treatment was
